Segment Information (Tables)

9 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Segment Revenue, Operating income (loss) and Depreciation and Amortization

Segment revenue, operating income (loss), and depreciation and amortization were as follows:

	Three Months Ended June 30,						Nine Months Ended June 30,
(In thousands)	2023			2022			2023			2022
Revenue:
Medical Device	$	46,014		$	17,528		$	84,739		$	52,889
In Vitro Diagnostics		6,469			7,326			19,875			21,074
Total revenue	$	52,483		$	24,854		$	104,614		$	73,963
Operating income (loss):
Medical Device	$	21,777		$	(7,308	)	$	7,483		$	(16,712	)
In Vitro Diagnostics		2,866			3,387			9,450			10,262
Total segment operating income (loss)		24,643			(3,921	)		16,933			(6,450	)
Corporate		(3,231	)		(3,222	)		(9,333	)		(9,034	)
Total operating income (loss)	$	21,412		$	(7,143	)	$	7,600		$	(15,484	)
Depreciation and amortization:
Medical Device	$	1,997		$	2,020		$	5,883		$	6,347
In Vitro Diagnostics		78			88			230			260
Corporate		76			98			252			295
Total depreciation and amortization	$	2,151		$	2,206		$	6,365		$	6,902